What is ENCHANTED?
The ENCHANTED study is a global public health study into acute ischaemic stroke aiming to improve the treatment of stroke which affects 15 million people worldwide causing premature death and disability. One in 10 people with stroke die in hospital, with many more suffering ongoing disability, highlighting the need for better treatments. Effective treatment of acute ischemic stroke could potentially improve the chances of survival and living without disability.
The ENCHANTED study is being conducted in 15 countries and began in 2012.
The study consists of two parts, each of which involves the evaluation of a modification of the usual form of treatment.
Part A of the study examines whether low-dose (0.6 mg/kg) rtPA gives the same or a better chance of a person surviving stroke and living without disability compared to the standard-dose (0.9 mg/kg) of rtPA that is used in most parts of the world. Part A finished recruitment on 17 August 2015 with more than 3300 patients randomised into this part of the study.
Part B of the study will examine whether lowering blood pressure levels quickly, and then controlling them to a level that is lower than is usually recommended, will improve the chances of a person surviving stroke and living without disability.
In this website, you will be able to find information on the study, recruitment updates, download our newsletters, and read about the latest news and results.